ARTICLE | Company News
FDA approves Novo Nordisk's PrandiMet
June 25, 2008 12:23 AM UTC
FDA approved an NDA from Novo Nordisk (NYSE:NVO; CSE:NVO) for PrandiMet repaglinide/metformin to treat Type II diabetes. Sciele (NASDAQ:SCRX) has exclusive U.S. rights to market PrandiMet and Novo Nor...